Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol Propionate Foam, 0.05% in Subjects 12 to Less Than 18 Years of Age With Plaque Psoriasis Receiving Two Weeks of Treatment
Latest Information Update: 10 Jul 2023
At a glance
- Drugs Ulobetasol (Primary)
- Indications Plaque psoriasis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Mayne Pharma Group
Most Recent Events
- 14 Jan 2020 Status changed from recruiting to completed.
- 01 Jul 2019 New trial record